Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

634 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
Cheung VTF, Gupta T, Olsson-Brown A, Subramanian S, Sasson SC, Heseltine J, Fryer E, Collantes E, Sacco JJ, Pirmohamed M, Simmons A, Klenerman P, Tuthill M, Protheroe AS, Chitnis M, Fairfax BP, Payne MJ, Middleton MR, Brain O. Cheung VTF, et al. Among authors: middleton mr. Br J Cancer. 2020 Jul;123(2):207-215. doi: 10.1038/s41416-020-0882-y. Epub 2020 May 18. Br J Cancer. 2020. PMID: 32418993 Free PMC article.
Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles.
Ye W, Olsson-Brown A, Watson RA, Cheung VTF, Morgan RD, Nassiri I, Cooper R, Taylor CA, Akbani U, Brain O, Matin RN, Coupe N, Middleton MR, Coles M, Sacco JJ, Payne MJ, Fairfax BP. Ye W, et al. Among authors: middleton mr. Br J Cancer. 2021 May;124(10):1661-1669. doi: 10.1038/s41416-021-01310-3. Epub 2021 Mar 15. Br J Cancer. 2021. PMID: 33723392 Free PMC article.
Assessing outcomes in palliative chemotherapy.
Cattell E, Arance A, Middleton M. Cattell E, et al. Among authors: middleton m. Expert Opin Pharmacother. 2002 Jun;3(6):693-700. doi: 10.1517/14656566.3.6.693. Expert Opin Pharmacother. 2002. PMID: 12036408 Review.
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Westwell S, Casasola R, Chao D, Maraveyas A, Patel PM, Ottensmeier CH, Farrugia D, Humphreys A, Eccles B, Young G, Barker EO, Harman C, Weiss M, Myers KA, Chhabra A, Rodwell SH, Dunn JA, Middleton MR; AVAST-M Investigators; Nathan P, Lorigan P, Dziewulski P, Holikova S, Panwar U, Tahir S, Faust G, Thomas A, Corrie P, Sirohi B, Kelly C, Middleton M, Marples M, Danson S, Lester J, Marshall E, Ajaz M, Houston S, Board R, Eaton D, Waterston A, Nobes J, Loo S, Gray G, Stubbings H, Gore M, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Marsden J, Westwell S, Casasola R, Chao D, Maraveyas A, Marshall E, Patel P, Ottensmeier C, Farrugia D, Humphreys A, Eccles B, Dega R, Herbert C, Price C, Brunt M, Scott-Brown M, Hamilton J, Hayward RL, Smyth J, Woodings P, Nayak N, Burrows L, Wolstenholme V, Wagstaff J, Nicolson M, Wilson A, Barlow C, Scrase C, Podd T, Gonzalez M, Stewart J, Highley M, Wolstenholme V, Grumett S, Goodman A, Talbot T, … See abstract for full author list ➔ Corrie PG, et al. Among authors: middleton mr, middleton m. Ann Oncol. 2018 Aug 1;29(8):1843-1852. doi: 10.1093/annonc/mdy229. Ann Oncol. 2018. PMID: 30010756 Free PMC article. Clinical Trial.
VCAM-1-targeted MRI Improves Detection of the Tumor-brain Interface.
Cheng VWT, de Pennington N, Zakaria R, Larkin JR, Serres S, Sarkar M, Kirkman MA, Bristow C, Croal P, Plaha P, Campo L, Chappell MA, Lord S, Jenkinson MD, Middleton MR, Sibson NR. Cheng VWT, et al. Among authors: middleton mr. Clin Cancer Res. 2022 Jun 1;28(11):2385-2396. doi: 10.1158/1078-0432.CCR-21-4011. Clin Cancer Res. 2022. PMID: 35312755 Free PMC article.
A phase 2 study of vatalanib in metastatic melanoma patients.
Cook N, Basu B, Biswas S, Kareclas P, Mann C, Palmer C, Thomas A, Nicholson S, Morgan B, Lomas D, Sirohi B, Mander AP, Middleton M, Corrie PG. Cook N, et al. Among authors: middleton m. Eur J Cancer. 2010 Oct;46(15):2671-3. doi: 10.1016/j.ejca.2010.07.014. Epub 2010 Aug 25. Eur J Cancer. 2010. PMID: 20800475 Clinical Trial.
NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus.
Chen JL, Dawoodji A, Tarlton A, Gnjatic S, Tajar A, Karydis I, Browning J, Pratap S, Verfaille C, Venhaus RR, Pan L, Altman DG, Cebon JS, Old LL, Nathan P, Ottensmeier C, Middleton M, Cerundolo V. Chen JL, et al. Among authors: middleton m. Int J Cancer. 2015 Mar 15;136(6):E590-601. doi: 10.1002/ijc.29118. Epub 2014 Aug 14. Int J Cancer. 2015. PMID: 25081390 Clinical Trial.
Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma.
Fairfax BP, Taylor CA, Watson RA, Nassiri I, Danielli S, Fang H, Mahé EA, Cooper R, Woodcock V, Traill Z, Al-Mossawi MH, Knight JC, Klenerman P, Payne M, Middleton MR. Fairfax BP, et al. Among authors: middleton mr. Nat Med. 2020 Feb;26(2):193-199. doi: 10.1038/s41591-019-0734-6. Epub 2020 Feb 10. Nat Med. 2020. PMID: 32042196 Free PMC article.
634 results